Polycystic Ovary Syndrome (PCOS) and Other Androgen Excess–Related Conditions: Can Changes in Dietary Intake Make a Difference?

Abstract

Polycystic ovary syndrome (PCOS) is a condition that involves the excess production of androgens. It affects up to 10% of all American women and can lead to the development of acne, hirsutism, and infertility. It has also been associated with coronary heart disease, diabetes, and metabolic syndrome. Over half of the women who are diagnosed with PCOS are overweight or obese. Recommendations are made for overweight/obese women to lose weight via diet and exercise. Women with PCOS should also consider maintaining a diet that is patterned after the type 2 diabetes diet. This diet includes an increase in fiber and a decrease in refined carbohydrates, as well as a decrease in trans and saturated fats and an increase in ω-3 andω -9 fatty acids. Foods that contain anti-inflammatory compounds (fiber,ω -3 fatty acids, vitamin E, and red wine) should also be emphasized. Evidence is provided for the impact of these dietary changes on improvements in the androgen profile of PCOS patients.

Get full access to this article

View all access options for this article.

References

Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2005 ;90:1929– 1935.

Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999 ;84:1897– 1899.

Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352:1223– 1236.

Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2006;20:193– 205.

Lowe P, Kovacs G, Howlett D. Incidence of polycystic ovaries and polycystic ovary syndrome amongst women in Melbourne, Australia. Aust N Z J Obstet Gynaecol. 2005 ;45:17– 19.

U.S. Department of Health and Human Services. Women's Health.Gov. Available at http://www.4women.gov/faq/pcos.htm#d. Accessed August 8, 2007.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 ;81:19– 25.

Zawadski JK, Dunaif A, Givens JR, Haseltine F. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Chang RJ, Heindel JJ, Dunaif A, eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific; 1992:377– 384.

10.

Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity of serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol. 1994;41:473– 481.

11.

Samojlik E, Kirschner MA, Silber D, Schneider G, Ertel NH. Elevated production and metabolic clearance rates of androgens in morbidly obese women. J Clin Endocrinol Metab. 1984 ;49:949– 954.

12.

Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril. 1988;50:197– 212.

13.

Nestler JE, McClanahan MA, Clore JN, Blackard WG. Insulin inhibits adrenal 17,20-lyase activity in man. J Clin Endocrinol Metab. 1992;74:362– 367.

14.

Yen SS, Vela P, Rankin J. Inappropriate secretion of follicle-stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab. 1970 ;30:435– 442.

15.

Yen SS. The polycystic ovary syndrome. Clin Endocrinol (Oxf). 1980;12:177– 207.

16.

Peiris AN, Mueller RA, Struve MF, Smith GA, Kissebah AH. Relationship to androgenic activity to splanchnic insulin metabolism and peripheral glucose utilization in premenopausal women. J Clin Endocrinol Metab. 1987;64:162– 169.

17.

Jacobs HS, Conway GS. Leptin, polycystic ovaries and polycystic ovary syndrome. Hum Reprod Update. 1999 ;5:166– 171.

18.

Liepa G, Basu H. C-reactive proteins and chronic disease: what role does nutrition play? Nutr Clin Pract. 2003 ;18:227– 233.

19.

Kelly CJ, Lyall H, Petrie JR, Gould GW, Connell J, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001 ;86:2453– 2455.

20.

Fogel RB, Malhotra A, Pillar G, Pittman SD, Dunaif A, White DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol. 2001 ;86:1175– 1180.

21.

Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1985 ;61:946– 951.

22.

Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol. 1992 ;37:119– 125.

23.

Norman RJ, Hague WM, Masters SC, Wang XJ. Subjects with polycystic ovaries without hyperandrogenemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. Hum Reprod. 1995;10:2258– 2261.

24.

Dahlgreen E, Janson PO, Johansson S, Lapidus L, Lindstedt G, Tengborn L. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril. 1994 ;61:455– 460.

25.

Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-I) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol. 1996;45:623– 629.

26.

Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle aged women. Arterioscler Thromb Vasc Biol. 2000;20:2414– 2421.

27.

Kelestimur F, Unluhizarci K, Baybuga H, Atmaca H, Bayram F, Sahin Y. Prevalence of polycystic ovarian changes and polycystic ovarian syndrome in pre-menopausal women with treated type 2 diabetes. Fertil Steril. 2006;86:405– 410.

28.

Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999 ;84:4006– 4011.

29.

Solomon CG. The epidemiology of polycystic ovary syndrome: prevalence and associated risks. Endocrinol Metab Clin North Am. 1999;28:247– 263.

30.

Blan A. Polycystic ovary syndrome and cancer. Hum Reprod Update. 2001;7:522– 525.

31.

Blank SK, McCartney CR, Marshall JC. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum Reprod Update. 2006;12:351– 361.

32.

Nestle JE, Jakubowicz DJ, de Vargas AF, Brik AC, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositologlycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998;83:2001– 2005.

33.

Alvarez-Blasco F, Botella-Carretero JI, San Millan JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovarian syndrome in overweight and obese women. Arch Intern Med. 2006;166:2081– 2086.

34.

Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschop M, Pasquali R. Plasma ghrelin, obesity and polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab. 2002;87:5625– 5629.

35.

Panidis D, Farmakiotis D, Koliakos G, et al. Comparative study of plasma ghrelin levels in women with polycystic ovary syndrome, in hyperandrogenic women and in normal controls. Hum Reprod. 2005;20:2127– 2132.

36.

Glintborg D, Andersen M, Hagen C, et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS), adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol. 2006;155:337– 345.

37.

Brzechffa PR, Jakimiuk AJ, Agarwal SK, Weitsman SR, Buyalos RP, Magoffin DA. Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1996 ;81:4166– 4169.

38.

Halaas JL, Gajiwala KS, Maffei M, et al. Weight reducing effects of the plasma protein encoded by the obese gene. Science. 1995 ;269:543– 546.

39.

Park K, Park KS, Kim M, et al. Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract. 2004 ;63:135– 142.

40.

Segal KR, Landt M, Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes. 1996;45:988– 991.

41.

Vauhkonen I, Niskanen L, Haffner S, Kainulainen S, Uusitupa M, Laasko M. Insulin resistant phenotype is associated with high serum leptin levels in offspring of patients with non-insulin-dependant diabetes mellitus. Eur J Endocrinol. 1998 ;139:598– 604.

42.

Larsson H, Elmstahl S, Ahren B. Plasma leptin correlate to islet function independently of body fat in post-menopausal women. Diabetes. 1996;45:1580– 1584.

43.

Holmang A, Svedberg J, Jennische E, Bjorntorp P. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol. 1990 ;259:E555– E560.

44.

Paik SG, Michelis MA, Kim YT, Shin S. Induction of insulin-independent diabetes: inhibition of estrogens and potentiation by androgens. Diabetes. 1982 ;31:724– 729.

45.

Coleman DL, Leiter EH, Applezweig N. Therapeutic effects of dehydroepiandrosterone metabolites in diabetic mutant mice. Endocrinology. 1984 ;115:239– 243.

46.

Leiter EH, Beamer WG, Coleman DL, Longcope C. Androgenic and estrogenic metabolites in serum of mice fed dehydroepiandrosterone: relationship to antihyperglycemic effects. Metabolism. 1987 ;36:863– 869.

47.

Barrett-Connor E, Ferrara A. Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1996 ;81:59– 64.

48.

Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril. 2000 ;73:150– 156.

49.

Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol. 1992 ;36:105– 111.

50.

Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol. 2005 ;62:644– 649.

51.

Cussons AJ, Stuckey BG, Walsh JP, Burke V, Norman RJ. Polycystic ovarian syndrome: marked differences between endocrinologists and gynaecologists in diagnosis and management. Clin Endocrinol (Oxf). 2005;62:289– 295.

52.

Slyper AH. Childhood obesity, adipose tissue distribution, and the pediatric practitioner. Pediatrics. 1998 ;102:e4 .

53.

Morales AJ, Laughlin GA, Butzow T, Maheshwari H, Baumann G, Yen SS. Insulin somatotropic and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab. 1996;81:2854– 2864.

54.

National Institutes of Health. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health;2000 . NIH Publication No. 00–4084.

55.

Wright CE, Zborowski JV, Talbott EO, McHugh-Pemu K, Youk A. Dietary intake, physical activity, and obesity in women with polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2004 ;28:1026– 1032.

56.

Berrino F, Bellati C, Secreto G, et al. Reducing bioavailable sex hormones through a comprehensive change in diet: the Diet and Androgens (DIANA) Randomized Trial. Cancer Epidemiol Biomarkers Prev. 2001;10:25– 33.

57.

Basu H, Pernecky S, Sengupta A, Liepa GU. Coronary heart disease: how do the benefits of omega-3 fatty acids compare with those of aspirin, alcohol/red wine, and statin drugs? J Am Oil Chem Soc. 2006 ;83:985– 997.

58.

Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman CL, Legro RS. A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil Steril. 2004;81:630– 637.

59.

Kasim-Karakas SE, Cunningham WM, Tsodikov A. Relation of nutrients and hormones in polycystic ovary syndrome. Am J Clin Nutr. 2007;85:688– 694.

60.

Meade SJ, Reid EA, Gerrard JA. The impact of processing on the nutritional quality of food proteins. J AOAC Int. 2005 ;88:904– 922.

61.

Stein K. Polycystic ovarian syndrome: what it is and why registered dietitians need to know. J Am Diet Assoc. 2006 ;106:1738– 1741.

62.

Mavropoulos JC, Yancy WS, Hepburn J, Westman EC. The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study. Nutr Metab. 2005 ;2:35– 46.

63.

Smith RN, Mann NJ, Braue A, Makelainen H, Varigos GA. A low-glycemic-load diet improves symptoms in acne vulgaris patients: a randomized controlled trial. Am J Clin Nutr. 2007 ;86:107– 115.

64.

Wang C, Catlin DH, Starcevis B, et al. Low-fat high-fiber diet decreased serum and urine androgens in men. J Clin Endocrinol Metab. 2005;90:3550– 3559.

65.

Kasim-Karakas SE, Almario RU, Gregory L, Wong R, Todd H, Lasley BL. Metabolic and endocrine effects of a PUFA rich diet in PCOS. J Clin Endocrinol Metab. 2004;89:615– 620.

66.

Bhathena SJ, Berlin E, Judd JT, et al. Effects of omega 3 fatty acids and vitamin E on hormones involved in carbohydrate and lipid metabolism in men. Am J Clin Nutr. 1991 ;54:684– 688.

67.

Thys-Jacobs S, Donovan D, Papadopoulos A, Sarrel P, Bilezikian JP. Vitamin D and calcium dysregulation in polycystic ovarian syndrome. Steroids. 1999;64:430– 435.

68.

Muneyyirci-Delale O, Nacharaju VL, Dalloul M, et al. Divalent cations in women with PCOS: implications for cardiovascular disease. Gynecol Endocrinol. 2001 ;15:198– 201.

69.

Bakken NA, Hunt CD. Dietary boron decreases peak pancreatic in situ insulin release in chicks and plasma insulin concentrations in rats regardless of vitamin D or magnesium status. J Nutr. 2003 ;133:3577– 3583.

70.

Nielsen FH, Gallagher SK, Johnson LK, Nielsen EJ. Boron enhances and mimics some effects of estrogen therapy in postmenopausal women. J Trace Elem Exp Med. 1992 ;5:237– 246.

71.

Lucidi RS, Thyer AC, Easton CA, Holden AE, Schenken RS, Brzyski RG. Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril. 2005;84:1755– 1757.

72.

Lydic ML, McNurlan M, Bembo S, Mitchell L, Komaroff E, Gelato M. Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. Fertil Steril. 2006 ;86:243– 246.

73.

Mahajan SK, Abbasi AA, Prasad AS, Rabbani P, Briggs WA, McDonald FD. Effect of oral zinc therapy on gonadal function in hemodialysis patients: a double blind study. Ann Intern Med. 1982 ;97:357– 361.

74.

Prasad AS, Mantzoros CS, Beck FW, Hess JW, Brewer GJ. Zinc status and serum testosterone levels of healthy adults. Nutrition. 1996 ;12:344– 348.

75.

El-akawi Z, Abdel-Latif N, Abdul-Razzak K. Does the plasma level of vitamins A and E affect acne condition? Clin Exp Dermatol. 2006;31:430– 434.

76.

Billaudel B, Delbancut A, Sutter B, Faure A. Mechanism of action of 1,25 dihydroxy-vitamin D3 on islet insulin secretion from D3 deficient rats. In: Norman AW, Bouillon R, Thomasset M, eds. Vitamin D: Gene Regulation, Structure-Function Analysis, and Clinical Application. New York, NY: W. de Gruyter; 1991:337– 338.

77.

Baynes KC, Boucher BJ, Feskens EJ, Kroumhout D. Vitamin D, glucose tolerance and insulinaemia in elderly men. Diabetologia. 1997 ;40:344– 347.

78.

Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract. 1995 ;27:181– 188.

79.

Ishida H, Seino Y, Tsuda K, et al. Circulating levels of vitamin D metabolites in patients with hyperinsulinemia. Hum Nutr Clin Nutr. 1984;38:473– 475.

80.

Hahn S, Haselhorst U, Tan S, et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with PCOS. Exp Clin Endocrinol Diabetes. 2006 ;114:577– 583.

81.

Bourlon PM, Billaudel B, Faure-Dussert A. Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol. 1999;160:87– 95.

82.

Brai HPS, Bano G, Brincat M, et al. 1,25 Dihydroxyvitamin D3 has a direct effect on steroid production from human theca cells. Endocrine Abstracts. 2003 ;5:P211 .

83.

De Felici M, Dolci S, Siracusa G. An increase of intracellular free Ca²⁺ is essential for spontaneous meiotic resumption by mouse oocytes. J Exp Zool. 1991 ;260:401– 405.

84.

Bae IH, Channing CP. Effect of calcium ion on the maturation of cumulus-enclosed pig follicular oocytes isolated from medium sized graafian follicles. Biol Reprod. 1985 ;33:79– 87.

85.

Adebamowo CA, Spiegelman D, Danby FW, Frazier AL, Willett WC, Holmes MD. High school dietary dairy intake and teenage acne. J Am Acad Dermatol. 2005;52:207– 214.

86.

Aqel MB, Gharaibah MN, Salhab AS. Direct relaxant effects of garlic juice on smooth and cardiac muscles. J Ethnopharmacol. 1991 ;33:13– 19.

87.

Bordia A, Verma SK, Vyas AK, et al. Effect of essential oil of onion and garlic on experimental atherosclerosis in rabbits. Atherosclerosis. 1977 ;26:379– 386.

88.

Chang MLW, Johnson MA. Effects of garlic on carbohydrate metabolism and lipid synthesis in rats. J Nutr. 1980 ;110:931– 936.

89.

Chi MS, Koh ET, Stewart TJ. Effects of garlic on lipid metabolism in rats fed cholesterol or lard. J Nutr. 1982 ;112:241– 248.

90.

Qureshi AA, Abuirmeileh N, Din ZZ, Elson CE, Burger WC. Inhibition of cholesterol and fatty acid biosynthesis in liver enzymes and chicken hepatocytes by polar fractions of garlic. Lipids. 1983 ;18:343– 348.

91.

Shoetan A, Augusti KT, Joseph PK. Hypolipidemic effects of garlic oil in rats fed ethanol and a high lipid diet. Experientia. 1984 ;40:261– 263.

92.

Mang B, Wolter M, Schmitt B, et al. Effects of a cinnamon extract on plasma glucose, HbA and serum lipids in diabetes mellitus type 2. Eur J Clin Invest. 2006 ;36:340– 344.

93.

Wang JG, Anderson RA, Graham GA, et al. The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study. Fertil Steril. 2007 ;88:240– 243.

94.

Cadoux-Hudson TA, Few JD, Imms FJ. The effect of exercise on the production and clearance of testosterone in well trained young men. Eur J Appl Physiol. 1985 ;54:321– 325.

95.

Brownlee KK, Viru M, Viru AM, Behr MB, Hackney AC. Exercise and the relationship between circulating cortisol and testosterone concentrations in men. Phys Educ Sport. 2006 ;50:30– 33.